RESUMEN

Introduction: This study aimed to describe the evolution of bone regeneration in children with hip osteonecrosis associated with sickle cell disease, treated with bone marrow-derived mesenchymal stem cell implants at the Professor Edgar Santos University Hospital Complex. Materials and methods: A non-randomized clinical trial was conducted with 48 patients of both sexes, aged between 11 and 18 years, diagnosed with femoral head osteonecrosis secondary to sickle cell disease. Patient selection was based on strict criteria, including confirmed diagnosis of sickle cell anemia and a stage of osteonecrosis compatible with the proposed treatment. Bone regeneration assessment was performed through radiographic examinations and magnetic resonance imaging, following the Ficat & Arlet criteria and the Salter-Thompson classification. Results: Statistical analysis revealed a significant association between the patients' age and positive treatment outcomes, suggesting that autologous bone marrow cell implantation is a safe and effective approach in the early stages of osteonecrosis. The majority of patients (87.5%) reported complete pain relief, while 10.42% experienced significant symptom improvement. Only one patient (2.08%) did not observe improvement. The results indicate that cell therapy can regenerate or slow the progression of bone necrosis, reducing the need for more invasive surgical procedures. Conclusion: The study demonstrates the potential of bone marrow-derived mesenchymal stem cell implantation in treating hip osteonecrosis in children with sickle cell disease, emphasizing the importance of long-term monitoring of bone structure stability.

RESUMEN

OBJECTIVES: To describe the incidence by gender and region, lethality, and costs associated with the treatment of femoral fractures in the elderly (≥ 60 years) hospitalized in the Unified Health System (SUS) of Brasil between 2008 and 2018. METHODS: This is a cross-sectional, descriptive, retrospective study of hospitalizations of elderly people due to femoral fractures by analyzing secondary data obtained from the SUS Hospital Information System (SIH/SUS) between 2008 and 2018; for calculation of epidemiological coefficients, we used information from demographic censuses (2000 and 2010) of the Brazilian Geography and Statistics Institute (IBGE). RESULTS: A total of 478,274 hospitalizations were recorded in the period; the incidence was 1.7 times higher in females (overall average of 274.91/100,000 for women and 161/100,000 for men). The Southeast region had the highest absolute number of hospitalizations and the South region presented the highest annual overall average incidence (224.02/100,000). The average annual cost for SUS for the treatment of femoral fractures in the elderly was R$ 99,718,574.30. CONCLUSIONS: In the evaluated period (2008-2018), femoral fractures in the elderly had a high incidence (478,274 hospitalizations; 224.02 cases/100,000 elderly), a predominance of females (1.7F/1.0M), a higher absolute number of hospitalizations in the Southeast region and a higher incidence in the South region; the lethality was high (an increase of 17.46%; overall mean coefficient of 4.99%/year); and the costs for the SUS were huge (an increase of 126.24%; average annual expenditure of R$ 99,718,574.30).

Asunto(s)

RESUMEN

SUMMARY OBJECTIVES: To describe the incidence by gender and region, lethality, and costs associated with the treatment of femoral fractures in the elderly (≥ 60 years) hospitalized in the Unified Health System (SUS) of Brasil between 2008 and 2018. METHODS: This is a cross-sectional, descriptive, retrospective study of hospitalizations of elderly people due to femoral fractures by analyzing secondary data obtained from the SUS Hospital Information System (SIH/SUS) between 2008 and 2018; for calculation of epidemiological coefficients, we used information from demographic censuses (2000 and 2010) of the Brazilian Geography and Statistics Institute (IBGE). RESULTS: A total of 478,274 hospitalizations were recorded in the period; the incidence was 1.7 times higher in females (overall average of 274.91/100,000 for women and 161/100,000 for men). The Southeast region had the highest absolute number of hospitalizations and the South region presented the highest annual overall average incidence (224.02/100,000). The average annual cost for SUS for the treatment of femoral fractures in the elderly was R$ 99,718,574.30. CONCLUSIONS: In the evaluated period (2008-2018), femoral fractures in the elderly had a high incidence (478,274 hospitalizations; 224.02 cases/100,000 elderly), a predominance of females (1.7F/1.0M), a higher absolute number of hospitalizations in the Southeast region and a higher incidence in the South region; the lethality was high (an increase of 17.46%; overall mean coefficient of 4.99%/year); and the costs for the SUS were huge (an increase of 126.24%; average annual expenditure of R$ 99,718,574.30).

RESUMO OBJETIVOS: Descrever a incidência por gênero e região, a letalidade e os custos associados ao tratamento de fraturas do fêmur em idosos (≥ 60 anos) internados no Sistema Único de Saúde (SUS) do Brasil entre 2008 e 2018. MÉTODOS: Estudo transversal, descritivo e retrospectivo das internações de idosos por fraturas do fêmur mediante análise dos dados secundários obtidos do Sistema de Informações Hospitalares do SUS (SIH/SUS) entre 2008 e 2018; para cálculo dos coeficientes epidemiológicos, utilizamos informações dos censos demográficos (2000 e 2010) do Instituto Brasileiro de Geografia e Estatística (IBGE). RESULTADOS: Foram registradas 478.274 mil internações no período. A incidência foi 1,7 vezes maior no gênero feminino (média geral de 274,91/100.000 para mulheres e 161/100.000 para homens). A região sudeste obteve maior número absoluto de internações e na região sul apresentou a maior incidência média geral anual (224,02/100.000). O custo médio anual do SUS para o tratamento das fraturas de fêmur em idosos foi de R$ 99.718.574,30. CONCLUSÕES: No período avaliado (2008-2018), as fraturas do fêmur em idosos apresentaram alta incidência (478.274 mil internações; 224,02 casos/100.000 idosos), predomínio do gênero feminino (1,7F/1,0M), maior número absoluto de internações na região sudeste e maior incidência na região sul; a letalidade foi elevada (aumento de 17,46%; média geral do coeficiente de 4,99%/ano); e, os custos para o SUS foram vultuosos (aumento de 126,24%, média anual de gastos de R$ 99.718.574,30).

Asunto(s)

RESUMEN

Introdução: O desenvolvimento da medicina com a descoberta do genoma humano revolucionou o conhecimento, o acompanhamento e o tratamento do câncer, proporcionando a utilização de novos métodos de diagnóstico e tratamento para diversos tipos de neoplasias e permitindo o aconselhamento genético. O aconselhamento genético, embora de difícil acesso, pode vir a permitir aos pacientes com suspeita de câncer hereditário a diminuição dos índices de morbidade e mortalidade por essa doença e proporcionar uma melhora na qualidade de vida dos pacientes. Objetivo: Demonstrar o estado da arte do aconselhamento genético em oncologia, utilizando a ferramenta digital da telemedicina. Método: Foi realizada uma revisão integrativa de literatura, entre dezembro de 2018 e março de 2019, a partir das bases de dados PubMed, SciELO e BIREME, por meio das palavras cadastradas no MeSH e nos Descritores em Ciências da Saúde (DeCS), respectivamente, em inglês, Genetic Counseling AND Telemedicine OR eHealth AND Oncology. Resultados: Foram encontrados 16 artigos; destes, oito foram excluídos. Restaram sete artigos que atendiam aos critérios de inclusão, demonstrando dados sobre a satisfação do paciente para com os serviços de aconselhamento genético voltados para o câncer, assim como suas vantagens e desvantagens. Conclusão: Embora ainda haja poucos estudos relatando experiências da prática do aconselhamento genético em oncologia, essa prática tem se demonstrado eficiente, de baixo custo e de boa aceitação do paciente e do profissional, suprindo necessidades principalmente nos locais de difícil acesso.

Introduction: The development of medicine and the discovery of the human genome revolutionized the knowledge, monitoring and treatment of cancer that favored the utilization of new methods of diagnosis, treatment for several types of neoplasms and genetic counseling. Although difficult to access, genetic counseling may allow the patients with suspected hereditary cancer, to reduce the rates of morbidity and mortality by this disease and ensure improvement in their quality of life. Objective: Demonstrate the state of the art of genetic counseling in oncology using the digital telemedicine tool. Method: An integrative literature review conducted between December 2018 and March 2019, using the PubMed, SciELO and BIREME databases, utilizing the words registered in the MeSH and Health Sciences Descriptors (DeCS), respectively, in English, Genetic Counseling AND Telemedicine OR eHealth AND Oncology. Results: 16 articles were found and of these, eight were excluded. Thus, seven articles that met the inclusion criteria showing data about patient satisfaction with cancer-oriented counseling services, its advantages and disadvantages remained. Conclusion: Although there are few studies addressing the experience of genetic counseling in oncology, this low cost practice has been shown to be efficient and well accepted by the patient and the professional, providing proper responses mainly in places of difficult access.

Introducción: El desarrollo de la medicina con el descubrimiento del genoma humano revolucionó el conocimiento, seguimiento y terapia del cáncer, permitiendo la utilización de nuevas técnicas de diagnóstico y terapias para diferentes tipos de neoplasias, además del asesoramiento genético. El asesoramiento genético, aunque de acceso difícil, puede permitir a los pacientes con sospechas de cáncer hereditario la disminución de los índices de morbilidad y mortalidad para esa enfermedad y proporcionar una mejora en su calidad de vida. Objetivo: Demostrar el estado del arte del asesoramiento genético en oncología utilizando la herramienta digital de la telemedicina. Método: Se realizó una revisión integrativa de literatura entre diciembre de 2018 y marzo de 2019, a partir de las bases de datos PubMed, SciELO y BIREME, por medio de las palabras catastradas en el MeSH y en el Descriptores de Ciencia de la Salud (DeCS), respectivamente, en inglés Genetic Counseling AND Telemedicine OR eHealth AND Oncology. Resultados: Se han encontrado 16 artículos; de estos, 8 fueron excluidos. Así, quedaron siete artículos que atendían a los criterios de inclusión demostrando datos sobre la satisfacción del paciente hacia con los servicios de asesoramiento genético dirigidos al cáncer, así como sus ventajas y desventajas. Conclusión: Aunque todavía hay pocos estudios relatando experiencias de la práctica del asesoramiento genético en oncología, esta práctica se ha demostrado eficiente, de bajo costo y de buena aceptación del paciente y del profesional, supliendo necesidades principalmente en los lugares de difícil acceso.

Asunto(s)